Babban wanda ya yi nasara a cikin rigakafin Covid-19 shine kamfanin Jamus BioNTech, ba Pfizer.
An yi abubuwa da yawa na Pfizer wanda ya kai kusan dala biliyan 100 a cikin kudaden shiga a cikin 2022, a babban bangare babu shakka godiya ga cutar ta Covid-19 da sanannen rigakafinta na Covid-19. Hakika, Rahoton kudi na baya-bayan nan game da kudin shiga na Pfizer ya nuna cewa tallace-tallacen rigakafin Covid-19 kaɗai ya kai kusan kashi 38 na waɗannan kudaden shiga na dala biliyan 100 (shafi na 30).
Amma kudaden shiga sune kudaden shiga. Abin da ke da mahimmanci, ba shakka, shine riba. Kuma rabin ribar da ake samu akan siyar da maganin rigakafinta na Covid-19 ba a zahiri riba ce ga Pfizer ba, sai dai farashi. Ta yaya hakan zai kasance?
Da kyau, saboda "Pfizer's" rigakafin Covid-19 ba gaskiya bane na Pfizer. A bisa doka, Pfizer ba ma masana'anta bane. Pfizer shine mai kera kwangilar da ke samarwa da tallata maganin a madadin ainihin mai shi, kamfanin Jamus BioNTech. Yana cewa haka dama akan alamar samfurin!
Kuma bisa ga sharuddan yarjejeniyar haɗin gwiwa tsakanin kamfanonin biyu, Pfizer na biyan BioNTech kashi 50 cikin XNUMX na ribar da ta samu don damar yin hakan. (Duba labarina "50/50 Raba: BioNTech da Pfizer Illusion" ko sashe na 4.9.1 na yarjejeniyar haɗin gwiwa nan.)
Bayan cire wannan kashi 50 na BioNTech kashi a matsayin "farashin siyarwa," Pfizer ya kiyasta cewa ragowar ribar da ta rage a kan siyar da allurar rigakafin Covid-19 tana cikin "mafi-20s a matsayin kaso na kudaden shiga." (Duba, alal misali, rahoton samun kuɗi na kwata nan, p. 4.)
Bari mu raba bambanci kuma mu ɗauki ribar 27.5 bisa dari na Pfizer. Aiwatar da wannan tazarar zuwa dala biliyan 37.8 na Pfizer a cikin 2022 kudaden shigar rigakafin Covid-19 yana ba da kusan dala biliyan 10.4 a cikin ribar.
Don haka, BioNTech ya sami adadin adadin? To, a'a. BioNTech ya samu Kara.
Daga cikin wasu dalilai masu yiwuwa, wannan shine saboda yayin da kamfanoni ke raba ribar 50-50 akan tallace-tallace a cikin Pfizer Yankin tallace-tallace, BioNTech kuma yana da kasuwannin tallace-tallacen da aka keɓe (Jamus da Turkiyya) kuma yana sayar da samfurin tare da haɗin gwiwar kamfanin Fosun Pharma na kasar Sin a sauran kasuwanni (Taiwan, Hong Kong, da Macau, amma har yanzu ba babban yankin China ba inda ba a taɓa ba da izinin maganin ba).
Don haka, nawa ne BioNTech ya samu? Zai yi kama da wuya kowa ya so sani - ko, a kowane hali, ba a cikin Twittersphere ba. Don haka, yayin da yawan kuɗin da Pfizer ya samu na 2022 ya kasance batun jigon tweet mai hoto ko bidiyo mai zagaya yanar gizo da sauri, tare da Elon Musk da kansa ma yana taimakawa wajen haɓaka ɗayan tare da wasu ma'ana guda biyu (duba. kasa), BioNTech ta ƙarshen Maris saki na Rahoton kudi na baya-bayan nan game da kudin shiga na 2022 ya wuce kusan ba a san shi ba akan Twitter da sauran wurare.
Koyaya, adadin ribar rigakafin Covid-2022 na kamfanin na 19 yana nan: wato, akan p. 161 karkashin "Sakamakon Aiki." Duba ƙasa. Babu buƙatar damuwa game da ribar da aka samu akan siyar da wasu samfuran - tunda BioNTech ba shi da wasu samfuran. € 12.95 biliyan. Ko kuma, a matsakaicin 2022 farashin canji, $ 13.6 biliyan. Don haka, kusan dala biliyan 3 da kashi 30 cikin ɗari fiye da Pfizer.
Kuma idan bambancin riba yana da mahimmanci, la'akari da bambancin gefe riba. BioNTech ya samu ribar Yuro biliyan 12.95 akan Yuro biliyan 17.3 a cikin kudaden shiga don samun ribar kashi 75 cikin dari! Wannan idan aka kwatanta da "mafi girma na 20s" na Pfizer akan kudaden shiga na rigakafin C-19 da kashi 34.6 akan duk kudaden shiga. (Dubi shafi na 20 na littafin Rahoton kudi Pfizer Inc don jimlar kuɗin shiga na kamfani kafin haraji.)
Ribar riba ta BioNTech tana nuna gaskiyar cewa tana ɗaukar kaɗan daga cikin farashin da ke tattare da samar da maganin. BioNTech yana aiwatar da wasu ayyukan samarwa don wasu kasuwanni: wato, samar da mRNA na roba, wanda take kerawa a wuraren samar da kayayyaki a Marburg.
Amma farashin da ke cikin wannan a bayyane ƙanana ne idan aka kwatanta da farashin da Pfizer ke ɗauka. Kuma ku tuna cewa duk farashin da Pfizer ke bayarwa yana shiga kuma ta haka yana haɓaka alkalumman kudaden shiga da aka ambata. Wannan shine dalilin da ya sa ribar BioNTech akan tallace-tallacen rigakafin ya fi na Pfizer yawa.
A cikin 2021, bambanci tsakanin BioNTech da Pfizer hauls ya ma fi girma, akasari saboda ɗimbin abubuwan biyan kuɗi da Pfizer ke bin BioNTech bisa ga sharuɗɗan yarjejeniyar haɗin gwiwa. Don haka, BioNTech ya sami Yuro biliyan 15 akan wani madaidaicin ribar kashi 79 cikin ɗari! (Dubi shafi na biyu a sama.)
A matsakaita farashin musaya na 2021, Yuro biliyan 15 daidai yake da kusan dala biliyan 17.75. Pfizer, idan aka kwatanta, ya sami kusan dala biliyan 10 a cikin ribar rigakafin Covid-19 a cikin 2021. (Don samun kuɗin Pfizer na 2021 da lissafin wannan adadi, duba "50/50 Raba")
Don haka, don haɗin 2021 da 2022, BioNTech ya yi fiye da dala biliyan 31 a cikin ribar rigakafin Covid-19 akan ribar kashi 77 cikin 20 idan aka kwatanta da Pfizer na sama da dala biliyan 27.5 akan kiyasin kashi 50 na ribar. Don haka, BioNTech ya sami ƙarin ribar kashi XNUMX akan ribar kusan sau uku mafi girma.
Ba sharri ga kamfanin da bai taba juyawa ba wani riba kafin 2021.
Zan iya samun "!!" daga Elon Musk?
-
Robert Kogon shi ne sunan alkalami na wani ɗan jarida da ake bugawa da yawa wanda ke yin rubuce-rubuce kan al'amuran Turai.
Duba dukkan posts
